BRPI0914902B8 - Composição farmacêutica para uso no tratamento de mal de parkinson - Google Patents

Composição farmacêutica para uso no tratamento de mal de parkinson

Info

Publication number
BRPI0914902B8
BRPI0914902B8 BRPI0914902A BRPI0914902A BRPI0914902B8 BR PI0914902 B8 BRPI0914902 B8 BR PI0914902B8 BR PI0914902 A BRPI0914902 A BR PI0914902A BR PI0914902 A BRPI0914902 A BR PI0914902A BR PI0914902 B8 BRPI0914902 B8 BR PI0914902B8
Authority
BR
Brazil
Prior art keywords
disease
parkinson
treatment
pharmaceutical composition
immediate release
Prior art date
Application number
BRPI0914902A
Other languages
English (en)
Portuguese (pt)
Inventor
Itschak Lamensdorf
Yoram Sela
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914902(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of BRPI0914902A2 publication Critical patent/BRPI0914902A2/pt
Publication of BRPI0914902B1 publication Critical patent/BRPI0914902B1/pt
Publication of BRPI0914902B8 publication Critical patent/BRPI0914902B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0914902A 2008-06-06 2009-06-07 Composição farmacêutica para uso no tratamento de mal de parkinson BRPI0914902B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5932608P 2008-06-06 2008-06-06
US61/059,326 2008-06-06
PCT/IL2009/000567 WO2009147681A1 (en) 2008-06-06 2009-06-07 Pharmaceutical compositions for treatment of parkinson's disease

Publications (3)

Publication Number Publication Date
BRPI0914902A2 BRPI0914902A2 (pt) 2017-06-20
BRPI0914902B1 BRPI0914902B1 (pt) 2022-02-22
BRPI0914902B8 true BRPI0914902B8 (pt) 2022-04-12

Family

ID=41051156

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914902A BRPI0914902B8 (pt) 2008-06-06 2009-06-07 Composição farmacêutica para uso no tratamento de mal de parkinson

Country Status (22)

Country Link
US (2) US8969417B2 (enExample)
EP (1) EP2303330B2 (enExample)
JP (1) JP5648216B2 (enExample)
KR (1) KR101613749B1 (enExample)
CN (1) CN102105169B (enExample)
AU (1) AU2009254730B2 (enExample)
BR (1) BRPI0914902B8 (enExample)
CA (1) CA2726833C (enExample)
CL (1) CL2010001358A1 (enExample)
CY (1) CY1119865T1 (enExample)
DK (1) DK2303330T4 (enExample)
ES (1) ES2659394T5 (enExample)
HU (1) HUE037974T2 (enExample)
LT (1) LT2303330T (enExample)
MX (1) MX2010013393A (enExample)
NO (1) NO2303330T3 (enExample)
NZ (1) NZ590291A (enExample)
PL (1) PL2303330T5 (enExample)
PT (1) PT2303330T (enExample)
RU (1) RU2540470C9 (enExample)
WO (1) WO2009147681A1 (enExample)
ZA (1) ZA201100034B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943489B2 (en) 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
JP6243351B2 (ja) * 2012-01-12 2017-12-06 ファーマ ツゥ ビー リミテッド パーキンソン病の固定投与量薬剤組合せ治療
WO2013168032A1 (en) * 2012-05-07 2013-11-14 Micro Labs Limited Pharmaceutical compositions comprising rasagiline
KR101320945B1 (ko) * 2012-07-03 2013-10-23 주식회사파마킹 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
MX2015003812A (es) * 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
EP2808023A1 (en) * 2013-05-30 2014-12-03 Université Pierre et Marie Curie (Paris 6) New drug for the treatment and/or prevention of depressive disorders
CN104473942A (zh) * 2014-12-12 2015-04-01 青岛大学 一种抗帕金森氏病的药物组合物
CA2986891C (en) 2015-05-26 2022-01-04 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
US20170143681A1 (en) * 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
EP3558378A4 (en) * 2016-12-22 2020-09-16 Synnerva Ltd. LOW DOSE COMBINATION OF MEDICINAL PRODUCTS FOR THE PREVENTION AND TREATMENT OF NEURAL DAMAGE
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
JP6596483B2 (ja) * 2017-12-28 2019-10-23 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
CN113924086A (zh) * 2019-04-17 2022-01-11 维奇健康科学有限责任公司 液体药物组合物
WO2020227646A1 (en) * 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
US20230028539A1 (en) 2019-12-06 2023-01-26 Shanghai Pharmaceuticals Holding Co., Ltd. Pharmaceutical composition, complementary kit and application thereof
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202227131A (zh) * 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
CN1436080A (zh) 2000-04-19 2003-08-13 利利艾科斯有限公司 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
KR20060124712A (ko) 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제
EP1901721A1 (en) 2005-06-23 2008-03-26 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20090325911A1 (en) 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
EP1970055B1 (en) * 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
BRPI0708071A8 (pt) 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
CN102160865A (zh) * 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
TW200820963A (en) 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
CN101573334A (zh) 2006-08-21 2009-11-04 普雷萨药品公司 用于治疗中枢神经系统障碍的多介质转运体抑制剂
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
ES2389456T3 (es) 2006-11-01 2012-10-26 Purdue Pharma Lp Compuestos de fenilpropionamida y uso de los mismos
EP2150239A1 (en) † 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
KR20110031181A (ko) 2011-03-24
RU2540470C9 (ru) 2015-07-20
EP2303330A1 (en) 2011-04-06
CA2726833A1 (en) 2009-12-10
JP5648216B2 (ja) 2015-01-07
DK2303330T4 (da) 2021-09-13
ES2659394T3 (es) 2018-03-15
RU2540470C2 (ru) 2015-02-10
US20150133513A1 (en) 2015-05-14
ZA201100034B (en) 2012-04-25
HUE037974T2 (hu) 2018-09-28
EP2303330B1 (en) 2017-11-15
WO2009147681A1 (en) 2009-12-10
EP2303330B2 (en) 2021-06-16
CN102105169A (zh) 2011-06-22
CA2726833C (en) 2016-03-22
MX2010013393A (es) 2011-06-21
NZ590291A (en) 2013-11-29
BRPI0914902A2 (pt) 2017-06-20
US8969417B2 (en) 2015-03-03
KR101613749B1 (ko) 2016-04-19
AU2009254730B2 (en) 2014-06-26
JP2011522035A (ja) 2011-07-28
LT2303330T (lt) 2018-04-10
PT2303330T (pt) 2018-02-12
CL2010001358A1 (es) 2011-08-19
RU2010154716A (ru) 2012-08-10
CN102105169B (zh) 2014-09-10
US20110230513A1 (en) 2011-09-22
BRPI0914902B1 (pt) 2022-02-22
AU2009254730A1 (en) 2009-12-10
PL2303330T3 (pl) 2018-04-30
ES2659394T5 (es) 2021-12-13
NO2303330T3 (enExample) 2018-04-14
CY1119865T1 (el) 2018-06-27
DK2303330T3 (en) 2018-02-26
PL2303330T5 (pl) 2021-10-25
US9259418B2 (en) 2016-02-16

Similar Documents

Publication Publication Date Title
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
WO2008116195A3 (en) Compositions comprising an sglt2 ingibitor for treating obesity
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
ECSP13012618A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
UY28271A1 (es) Compuestos químicos
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BRPI0916282B8 (pt) uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2668 DE 22/02/2022 QUANTO AO ENDERECO.